TCGA data revealed activating mutations and amplifications of PIK3CA in 18–28% of cases of serous cystadenocarcinoma, with enrichment of the signature of activated PI3K in a majority of cases irrespective of the subtype [31]. This evidence concerns the gene PIK3CA and cystadenocarcinoma.